Tweet
Pharmacoeconomics. 2016 Sep 19. [Epub ahead of print]
Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model.
Dolk C1, Eichner M2,3, Welte R4, Anastassopoulou A4, Van Bellinghen LA5, Poulsen Nautrup B6, Van Vlaenderen I5, Schmidt-Ott R4,7, Schwehm M8, Postma M9,10,11.
Author information
Abstract
BACKGROUND:
Seasonal influenza infection is primarily caused by circulation of two influenza A strain subtypes and strains from two B lineages that vary each year. Trivalent influenza vaccine (TIV) contains only one of the two B-lineage strains, resulting in mismatches between vaccine strains and the predominant circulating B lineage. Quadrivalent influenza vaccine (QIV) includes both B-lineage strains. The objective was to estimate the cost-utility of introducing QIV to replace TIV in Germany.
METHODS:
An individual-based dynamic transmission model (4Flu) using German data was used to provide realistic estimates of the impact of TIV and QIV on age-specific influenza infections. Cases were linked to health and economic outcomes to calculate the cost-utility of QIV versus TIV, from both a societal and payer perspective. Costs and effects were discounted at 3.0 and 1.5 % respectively, with 2014 as the base year. Univariate and probabilistic sensitivity analyses were conducted.
RESULTS:
Using QIV instead of TIV resulted in additional quality-adjusted life-years (QALYs) and cost savings from the societal perspective (i.e. it represents the dominant strategy) and an incremental cost-utility ratio (ICUR) of ?14,461 per QALY from a healthcare payer perspective. In all univariate analyses, QIV remained cost-effective (ICUR 98 and >99 % of the simulations from the societal and payer perspective, respectively.
CONCLUSION:
This analysis suggests that QIV in Germany would provide additional health gains while being cost-saving to society or costing ?14,461 per QALY gained from the healthcare payer perspective, compared with TIV.
PMID: 27647004 DOI: 10.1007/s40273-016-0443-7
[PubMed - as supplied by publisher]
Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model.
Dolk C1, Eichner M2,3, Welte R4, Anastassopoulou A4, Van Bellinghen LA5, Poulsen Nautrup B6, Van Vlaenderen I5, Schmidt-Ott R4,7, Schwehm M8, Postma M9,10,11.
Author information
Abstract
BACKGROUND:
Seasonal influenza infection is primarily caused by circulation of two influenza A strain subtypes and strains from two B lineages that vary each year. Trivalent influenza vaccine (TIV) contains only one of the two B-lineage strains, resulting in mismatches between vaccine strains and the predominant circulating B lineage. Quadrivalent influenza vaccine (QIV) includes both B-lineage strains. The objective was to estimate the cost-utility of introducing QIV to replace TIV in Germany.
METHODS:
An individual-based dynamic transmission model (4Flu) using German data was used to provide realistic estimates of the impact of TIV and QIV on age-specific influenza infections. Cases were linked to health and economic outcomes to calculate the cost-utility of QIV versus TIV, from both a societal and payer perspective. Costs and effects were discounted at 3.0 and 1.5 % respectively, with 2014 as the base year. Univariate and probabilistic sensitivity analyses were conducted.
RESULTS:
Using QIV instead of TIV resulted in additional quality-adjusted life-years (QALYs) and cost savings from the societal perspective (i.e. it represents the dominant strategy) and an incremental cost-utility ratio (ICUR) of ?14,461 per QALY from a healthcare payer perspective. In all univariate analyses, QIV remained cost-effective (ICUR 98 and >99 % of the simulations from the societal and payer perspective, respectively.
CONCLUSION:
This analysis suggests that QIV in Germany would provide additional health gains while being cost-saving to society or costing ?14,461 per QALY gained from the healthcare payer perspective, compared with TIV.
PMID: 27647004 DOI: 10.1007/s40273-016-0443-7
[PubMed - as supplied by publisher]